FY2025 · ended Dec 31, 2025 · Revenue $2.07M, +3.7% YoY · Filed Mar 30, 2026
Cyclerion Therapeutics, Inc. (KRSA) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $2.1 million and a net loss of $3.5 million.
Revenue (TTM)
$1.90M
Net income (TTM)
$-6.71M
-244.7% vs year-ago TTM
Operating cash flow (TTM)
$-4.45M
-57.4% vs year-ago TTM
Free cash flow
$-40.61M
-11.2% vs prior year
EPS (TTM)
$-1.73
-139.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
4.33M
+59.8% vs prior year
Net cash
$9.88M
FY 2022
Operating margin
-359.2%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KRSA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- MA
- Headquarters
- Waltham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1755237
- Former names
- Cyclerion Therapeutics, Inc. (until Aug 27, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $2.1M | $2.0M | $0 | $297,000 | $3.9M |
| Operating income | -$5.0M | -$3.6M | -$13.0M | -$18.5M | -$55.2M |
| Net income | -$3.5M | -$3.1M | -$5.3M | -$44.1M | -$51.6M |
| Diluted EPS | -$1.11 | -$1.21 | -$2.25 | -$20.28 | — |
| Operating cash flow | -$3.3M | -$4.3M | -$21.2M | -$40.6M | -$36.5M |
| Free cash flow | — | — | — | -$40.6M | -$36.5M |
| Total assets | $10.0M | $9.6M | $13.4M | $18.1M | $59.3M |
| Stockholders' equity | $9.1M | $8.8M | $11.3M | $10.5M | $48.2M |
| Cash and investments | $3.2M | $3.2M | $7.6M | $13.4M | $54.0M |
| Total debt | — | — | — | $3.5M | $3.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Results of operations, Unregistered share sale, Change to shareholder rights, Change in control, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure
|
Sep 11, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Shareholder vote results, Other events
|
Aug 27, 2026 | Aug 26, 2026 |
| 8-K |
Current report
Other events
|
Aug 25, 2026 | Aug 25, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 10-K/A | Amended annual report | Apr 30, 2026 | Dec 31, 2025 |
All 389 Cyclerion Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.